Jennifer Young

•Led development of international health policy analysis and advocacy on government pricing and reimbursement, universal health coverage, sustainable health care financing, and trade-related market access topics to advance innovative biopharmaceutical sector priorities with U.S. and foreign governments, sister associations (e.g., IFPMA, EFPIA, BIO), Dolder, and multilateral organizations including the World Health Organization (WHO), World Bank, and the Organization for Economic Cooperation and Development (OECD) •Co-led PhRMA's international biologics and biosimilars policy work group, including development of public policy platforms and advocacy strategies for use in priority markets and with the WHO. •Led international anti-counterfeiting advocacy on behalf of PhRMA, including development of industry proposals to promote access to safe medicines within the G8, APEC, and G20 summits. •Drove member company consensus to develop advocacy platforms, briefing papers, toolkits, and presentations on international health policy, regulatory, trade, and market access issues in coordination with academics, think tanks, patient groups, and third parties. •Briefed CEOs, senior management, and member companies on opportunities and risk mitigation strategies related to international market access, healthcare financing, government pricing and reimbursement, trade policy, international biologics and biosimilars, and anti-counterfeiting issues. •Represented PhRMA as an appointed advisor to the Industry Trade Advisory Committee (ITAC-3) for Chemicals, Pharmaceuticals, Health Science Products and Services with the U.S. Dept of Commerce and Office of the U.S. Trade Representative. •Managed academic, think tank, and consultant projects and associated budgets. •Directly supervised PhRMA staff.

•Led development and implementation of cross-divisional regional and global public and government affairs strategies to advance business objectives. •Mitigated risks/challenges to business by managing issues, monitoring policy developments, and developing briefing materials for senior executives including US CEO and Board members. •Identified opportunities to advance business priorities and drive growth through capacity building with governments and international institutions (e.g., World Health Organization, World Economic Forum). •Managed regional stakeholders and leveraged US and foreign governments, and trade associations to advance public and government affairs priorities related to intellectual property, pricing, market access, HTA, tendering, and trade policy issues in emerging markets. •Developed global public affairs cost containment toolkit to provide analytic support and build in-country government affairs capacity in Latin America, Canada, Europe, and Asia. •Co-chaired PhRMA International Market Access and Policy committee to shape industry market access objectives within bilateral and multilateral trade agreements.

•Managed International Market Access and Policy committee, and advanced market access and policy strategies on behalf of the biopharmaceutical industry in priority markets. •Developed and executed advocacy materials, position papers, issue briefs, and presentations on cost containment, pricing and reimbursement, trade policy, market access, and health system financing issues. •Led meetings with US and foreign governments to advance industry pricing and market access priorities. •Presented as an invited speaker to US and foreign governments, industry, and NGO conferences. •Built relationships with external stakeholders to support international market access and public policy priorities, including coordinating think tank network meetings in Europe and Asia. •Coordinated market access projects including: economic impact analysis of the pharmaceutical sector in emerging markets, a multi-stage project to quantify damages due to lacking IP enforcement, and advocacy for bilateral and multilateral trade agreements.

•Analyzed intellectual property (IP) policy, economic, and trade issues facing the biopharmaceutical industry to support Hill and multilateral advocacy (e.g., World Trade Organization, World Health Organization) •Developed policy papers, advocacy materials, presentations, talking points, and analytics on topics including compulsory licensing, patent linkage, data protection, access to medicines, and innovation. •Managed economic policy and research projects on the relationship between patent protection, foreign direct investment and technology transfer in developing countries with academics and think–tanks. •Briefed internal/external stakeholders on IP policy issues, including at IP Task Force meetings, and regional meetings in Asia and Europe. •Served as the principal liaison between the Policy and International departments within PhRMA, and managed a Global IP budget for international IP policy and research projects.

•Developed policy positions and briefing materials on intellectual property (IP) and market access issues in China, including for the first World Trade Organization case panel meeting in a US-China intellectual property dispute. •Built consensus across U.S. and foreign government agencies to coordinate the first China IP technical assistance conference with the U.S., EU, and Chinese governments, industry, and academia. •Drafted and negotiated policy positions, and briefed senior government officials on intellectual property, trade policy, and healthcare policy issues as part of high–level trade dialogues with China, Japan, and Taiwan. •Served as an invited speaker at public/private events on IP, market access, and trade policy issues. •Coordinated Ambassador’s IP Roundtable recruiting more than 250 government and industry participants, and organizing seven panel presentations featuring 40 speakers. •Briefed the U.S. Ambassador to China on key IP, economic, and trade policy issues, and represented USG at meetings with China’s Ministry of Commerce, Intellectual Property Office, and the Shanghai High Court. •Analyzed economic and legal issues related to anti–dumping and subsidy enforcement. •Participated in interagency meetings to develop negotiating strategies on government pricing and competitiveness issues facing multiple industry sectors in China. •Analyzed complex economic issues for the competition chapter of the U.S.–Korea Free Trade Agreement. •Coordinated a 200-company Under Secretarial Business Development Mission to India. •Participated in high–level trade meetings in Mumbai and Chennai, and presented a keynote speech with the US Consul General to government officials, chambers of commerce, and national media.

Dissertation with Merit: The Ethics of Insolvency: Personal Responsibility vs. Incentives for Entrepreneurship